The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-German minister sees COVID-19 vaccine shortage well into April

Thu, 28th Jan 2021 08:55

* Health minister: vaccine shortages to last at least 10
weeks

* Interior ministry preparing entry ban for risk countries

* 7-day incidence falls below 100 cases/100,000 people
(Adds timing of summit)

BERLIN, Jan 28 (Reuters) - Germany faces a shortage of
coronavirus shots well into April, its health minister said on
Thursday, and called for a summit with the country's state
leaders to discuss vaccinations as the government faced fresh
criticism over the pace of the roll-out.

Several people close to the talks told Reuters that the
meeting will take place on Monday.

"We will still have at least 10 tough weeks with a shortage
of vaccine," Jens Spahn said in a Tweet, adding the meeting
should focus on how Europe gets its fair share of shots and what
can be done to support the process.

Germany, like the rest of the European Union, is scrambling
to obtain shots as the West's biggest drugmakers slow deliveries
to the bloc due to production problems.

Germany's top-selling Bild newspaper described the problem
of procuring enough vaccines as a "scandal".

Meanwhile, popular approval of the government's handling of
the coronavirus crisis has dropped to 49%, its lowest since the
start of the pandemic, a poll for the Frankfurter Allgemeine
Zeitung showed.

Spahn said he wanted to invite pharmaceutical companies and
vaccine manufacturers to a meeting to discuss the way forward,
adding he recognised vaccine production was complex and
production could not be built up in a few weeks.

On Tuesday, Spahn supported European Union proposals to set
up a register of vaccine exports, as tensions grow with
AstraZeneca and Pfizer over sudden supply cuts
just a month after the EU started vaccinating citizens.

Germany reported 17,553 new coronavirus cases on Thursday,
bringing the total to 2,178,828, and another 941 deaths. The
seven-day incidence rate fell under 100 cases per 100,000 for
the first time since the end of October. The government wants it
to drop below 50.

Spahn has said that if cases continue to fall, schools and
nurseries should be the first to reopen after a lockdown
currently due to last until Feb. 14.

Germany is also preparing entry restrictions for travellers
from Britain, Brazil and South Africa, the interior ministry
said, and hopes to decide by Friday as concerns mount about more
contagious variants.

"We have to get ahead of the situation," Interior Minister
Horst Seehofer said on Twitter.

(Reporting by Emma Thomasson, Caroline Copley and Andreas
Rinke; Editing by Thomas Seythal, Alex Richardson and Giles
Elgood)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.